Laura S. Wood

TL;DR: Sunitinib-based therapy has the potential to modulate antitumor immunity by reversing MDSC-mediated tumor-induced immunosuppression and is correlated with reversal of type 1 T-cell suppression.

TL;DR: These data validate the model described by Motzer et al for survival in patients with previously untreated metastatic renal cell carcinoma and identify additional independent prognostic factors, which were prior radiotherapy and sites of metastasis.

TL;DR: The demonstration that sunitinib improved type-1 T-cell cytokine response in mRCC patients while reducing Treg function provides a basis for the rational combination of sunit inib and immunotherapy in m RCC.

TL;DR: Thyroid function test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted.

TL;DR: Recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy.